Clinical Trial Update: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) [Phase 2]

View source ↗

Summary

A Phase 2 SWOG Lung-MAP trial is evaluating combinations of targeted therapies for advanced non-small cell lung cancer with EGFR and MET gene changes. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Status: RECRUITING